The Effect of Sildenafil in Preterm Infants With Evolving Chronic Lung Disease
NCT ID: NCT00431418
Last Updated: 2015-09-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
20 participants
INTERVENTIONAL
2007-01-31
2012-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety of Sildenafil in Premature Infants
NCT03142568
Endovenous Sildenafil Early Management in Newborns Pulmonary Hypertension
NCT04912726
Study of Sildenafil to Treat Newborns With Persistent Pulmonary Hypertension
NCT01409031
Chronic Sildenafil for Severe Diaphragmatic Hernia
NCT00133679
A Study To Evaluate Safety And Efficacy Of IV Sildenafil In The Treatment Of Neonates With Persistent Pulmonary Hypertension Of The Newborn
NCT01720524
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Sildenafil oral solution.
Sildenafil
Sildenafil oral solution
2
Placebo oral solution.
Placebo
Placebo solution
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sildenafil
Sildenafil oral solution
Placebo
Placebo solution
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Suspected inborn error of metabolism
* Inhaled Nitric Oxide treatment during assessment
7 Days
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mercy Hospital for Women, Australia
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Kai Konig
Consultant Neonatologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kai König, MD
Role: PRINCIPAL_INVESTIGATOR
Mercy Hospital for Women
Charles P Barfield, MD
Role: PRINCIPAL_INVESTIGATOR
Mercy Hospital for Women
Chad C Andersen, MD
Role: PRINCIPAL_INVESTIGATOR
Mercy Hospital for Women
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mercy Hospital for Women
Heidelburg, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
R 06/34
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.